Patent Foramen Ovale

Publication Date: April 29, 2020

Key Points

Key Points

  • For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
  • For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.

Management

...Managem...

...Recommendation...

...eing considered for PFO closure, clinicians shoul...

...atients being considered for PFO closure, clinici...

...being considered for PFO closure,...

...ents being considered for PFO closure,...

...ect patients being considered for PFO closure th...

...tients being considered for PFO clos...

...patients being considered for PFO closure,...

...ng considered for PFO closure, clinicians may u...

Before undergoing PFO closure, patients...

...her risk alternative mechanism of strok...

Before undergoing PFO closure, patients should...

...nts with a PFO detected after stroke and n...

...atients younger than 60 years with a P...

...icians may inform patients that presence of a...

PFO closure may be offered in other populat...

...may be offered to younger patients...

...tient for whom PFO closure is being con...


...Recom...

...opt to receive medical therapy alone without P...

...n patients who would otherwise be considere...


...Management Algorithm...